This alliance will focus on improving service to pharmaceutical and research partners globally and advancing treatment options for patients across all therapeutic areas
Atlanta, Georgia and Toronto, Ontario – Nov. 17, 2021 – U.S.-based IACT Health and Canada-based LMC Manna Research today announced a strategic alliance to integrate their operations. As two of the clinical research industry’s most extensive site networks, the alliance creates one of the largest consolidated research networks in North America, with more than 40 sites, access to over 1.5 million patients, and more than 150 active investigators.
Shared technology, marketing, recruitment, business development, contracts, budgets, standard operating procedures, and more are expected to further expand the operational efficiencies that IACT Health and LMC Manna Research already offer the industry.
“We are thrilled to join forces with such a highly-qualified and reputable research organization that brings such deep experience and a proven track record of delivering on their clincal trials year after year,” said Dr. Jeff Kingsley, CEO of IACT Health. “Both companies share a commitment to quality, safety, patient satisfaction, and customer service that will position us as the preferred option for pharmaceutical and biotech companies, Contract Research Organizations (CROs), patients, and providers alike.”
“LMC Manna Research is excited about the opportunity to work with IACT Health’s talented team, who share our approach to integrated research sites and systems, and place strong emphasis on quality and patient experience,” said Karri Venn, President of LMC Manna Research. “Together, we will offer sponsors and CROs a single point of contact to perform their clinical studies across North America, while providing meaningful and strategic combined research operations across these two networks to create North America’s pre-eminent clinical research network.”
As the largest U.S. network of wholly-owned clinical research sites in the southeast U.S., IACT Health strives to revolutionize research by conducting research alongside routine healthcare, as well as urgent and emergency care, while creating outstanding clinical trial experiences, improving outcomes, and lowering the risk and net cost of studies. IACT Health’s proven enrollment is more than 212 percent of the average research site, as assessed by Tufts University. Since 2005, IACT Health has contributed to helping more than 80 medications achieve FDA approvals in areas such as oncology, cardiology, pulmonology, endocrinology, infectious disease, and pain.
Canada’s most extensive clinical research network, LMC Manna Research provides pharmaceutical companies and CROs with a single source approach to performing clinical trials across a full gamut of treatment areas. Its proven track record of fast start-up, high recruitment and regulatory compliance is supported by its ability to provide single-source contracting, integrated standard operating procedures, strong quality assurance and capabilities to deploy a national decentralized technology system across its entire network.
About IACT Health
IACT Health is a research management organization with 17 wholly owned and integrated clinical research offices in multiple cities across the Southeast United States. IACT conducts phase I-IV clinical research in over 30 therapeutic areas; inpatient and outpatient; pharmaceutical, biotechnology, and medical device trials. For 16 years, IACT Health has worked to revolutionize research by investing in the people and technology needed to deliver outstanding clinical trial experiences and has won numerous awards including Best Places to Work and for Diversity in Clinical Research.
More information about IACT Health can be found at https://iacthealth.com/
About LMC Manna Research
LMC Manna Research is an industry leader, providing phase I-IV clinical trial services across Canada at 22 active research sites. It is the largest clinical research site group in the country and one of the largest research site networks in the world. The company is also the world’s largest group specialized in diabetes, lipid, metabolic and endocrinology research. Over the past 24 years, the company has completed more than 1,800 studies to help evaluate hundreds of new drugs and treatments in more than 20,000 study participants and has won numerous awards for performance, quality, and innovation.
More information about LMC Manna Research can be found at http://lmcmannaresearch.com.